Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01209871 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma
A Phase 1 study of Lymphoplasmacytic Lymphoma, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT01209871: Active Phase 1 study of Lymphoplasmacytic Lymphoma, sponsored by M.D. Anderson Cancer Center.
NCT01209871 is a Phase 1 study of Lymphoplasmacytic Lymphoma that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 9 participants, below the 108-participant average among 18 other Lymphoplasmacytic Lymphoma trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01209871, a Phase 1 study of Lymphoplasmacytic Lymphoma, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial studies the side effects and best dose of vaccine therapy in treating patients with lymphoplasmacytic lymphoma. Vaccines made from a person's cancer cells may help the body build an effective immune response to kill cancer cells.
Primary Outcome
Toxicity type and severity will be summarized by frequency tables.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Autologous Lymphoma Immunoglobulin-derived scFv-chemokine DNA Vaccine
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2015-02-26 |
| Est. Completion | 2026-02-20 |
| Phase | Phase 1 |
What the registry record for NCT01209871 still lists
NCT01209871 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 108-participant average among 18 other Lymphoplasmacytic Lymphoma trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Lymphoplasmacytic Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01209871 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT01209871 about?
NCT01209871 is a clinical study titled "Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma". This phase I trial studies the side effects and best dose of vaccine therapy in treating patients with lymphoplasmacytic lymphoma. Vaccines made from a person's cancer cells may help the body build an effective immune response to kill cancer cells.
What is the current status of trial NCT01209871?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2015-02-26. Estimated completion is 2026-02-20.
What conditions does trial NCT01209871 study?
This clinical trial studies the following conditions: Lymphoplasmacytic Lymphoma.
What interventions are being tested in trial NCT01209871?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Autologous Lymphoma Immunoglobulin-derived scFv-chemokine DNA Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01209871?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01209871 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoplasmacytic Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01209871's enrollment target sits among peer trials
9 19th of 18 the lowest of 18 other Lymphoplasmacytic Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoplasmacytic Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
RECRUITING · Phase 1
-
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 1
-
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma
COMPLETED · Phase 1
-
Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL
COMPLETED · Phase 1
-
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI